Sionna Therapeutics, a clinical-stage biopharma focused on Cystic Fibrosis (CF) NBD1 stabilizers, reported Q3 2025 results following its February 2025 IPO, which yielded $199.6 million net proceeds.
Financial Performance & Operations: The nine-month period ended September 30, 2025, showed a widening Net Loss of \(54.8 million (up from \)45.8 million in 2024), driven primarily by a sharp increase in external Research and Development (R&D) expenses, which grew to \(32.9 million YTD. Stock-based compensation expense also rose significantly to \)8.24 million YTD. Despite operational losses, the c
...